Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
Superinvestors holding BLTE, Q2 2026
2 superinvestors report holding Belite Bio, Inc on Form 13F, worth $77.4M in total. Weight is Belite Bio, Inc's share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Maverick CapitalLee Ainslie | 0.6% | 396,311 | $61.0M | New |
| Duquesne Family OfficeStanley Druckenmiller | 0.4% | 106,100 | $16.3M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of BLTE each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
2 superinvestors holding at quarter end
Q1 2026
1 superinvestor holding at quarter end